Angiotensin-converting enzyme inhibitor for slowing progression of diabetic and nondiabetic kidney disease.
J Am Soc Nephrol
; 9(12 Suppl): S66-70, 1998 Dec.
Article
en En
| MEDLINE
| ID: mdl-11443771
ABSTRACT
A growing body of evidence suggests that agents that inhibit the angiotensin-converting enzyme are renoprotective. In experimental animal models of chronic renal injury, such renoprotection can virtually eliminate progression of the renal injury, provided that therapy is started at the time of injury. In humans with chronic renal injury, renoprotection has been successfully demonstrated only late in the course of the renal disease. The rate of progression to end-stage renal failure can be delayed, but progression continues at a slower pace. Further study is required to determine whether earlier intervention can better preserve nephron structure and function. A strategy for future trials is recommended. It emphasizes more sensitive outcome measures so as to achieve greater statistical power.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Inhibidores de la Enzima Convertidora de Angiotensina
/
Diabetes Mellitus
/
Enfermedades Renales
/
Fallo Renal Crónico
Límite:
Animals
/
Humans
Idioma:
En
Revista:
J Am Soc Nephrol
Asunto de la revista:
NEFROLOGIA
Año:
1998
Tipo del documento:
Article
País de afiliación:
Estados Unidos